Biologics contract manufacturers are investing at record pace—mammalian cell culture capacity is projected to grow 40.4% over five years—yet the market remains tight. The tension is not just volume. The BIOSECURE Act is forcing sponsors away from Chinese CDMOs into a narrower pool of qualified Western and allied manufacturers, while demand for complex formats like antibody-drug conjugates is outpacing the ability of most CDMOs to build specialized capability. The result is a two-tier market: large, well-capitalized platforms racing to add generic monoclonal antibody capacity, and mid-sized shops fighting for niche slots in cell therapy and biosimilars. A buyer's next RFP will land in a market where headline capacity growth masks real scarcity in the modalities and geographies that matter.
The expansion is real, but it lags the reshuffling
Average CMO 5-year expansion for mammalian cell culture was 40.4% in 2026, up from 33.8% in 2025. That is a meaningful acceleration. Yet manufacturing capacity—particularly for biologics and fill-finish operations—remains tight heading into 2026. The disconnect reflects two forces colliding: supply is growing, but demand is growing faster, and it is reshaping where that supply needs to be.
The BIOSECURE Act, signed into US law in late 2024, is the pivot point. Companies that relied on WuXi AppTec, WuXi Biologics, and other Chinese CDMOs for decades are now racing to secure alternative capacity in the US, Europe, South Korea, and India. This is not a gradual migration. Sponsors are moving programs now, not in 2028. That surge is hitting a Western CDMO base that, while expanding, is not distributed evenly. More than 84 percent of the $13.3 billion in disclosed manufacturing investment was directed to US facilities. US capacity is being built, but Europe and Asia-Pacific—where many sponsors also need redundancy—are not seeing proportional investment.
The result is a compressed timeline. Sponsors need capacity slots in 2026 and 2027, not 2029. A CDMO that promises to open a new suite in 2028 is not solving the problem for most programs in active development. Buyers are therefore facing a choice: accept longer timelines and higher costs with established players, or take on execution risk with smaller shops that have slots but less manufacturing track record.
Complex formats are the real bottleneck
One of the sharpest trends is the scramble for capability in antibody-drug conjugates and other complex formats, which demand specialized capability to combine a biologic, a potent payload, and a linker at pharmaceutical quality. This is where headline capacity numbers break down. A CDMO may have 20,000 liters of mammalian bioreactor space, but if that capacity is configured for simple mAbs, it does not help a sponsor with an ADC program. ADCs require dedicated suites, specialized linker handling, payload expertise, and often separate analytical capability. The same applies to cell and gene therapies and biosimilars.
Mid-sized CDMOs focus on niche areas like cell and gene therapy or biosimilars but face high entry barriers due to capital intensity and stringent regulatory requirements. That is the trap: the modalities where capacity is most constrained are also the ones where only a handful of players have earned the regulatory credibility to land a program. A sponsor with a novel cell therapy program cannot simply call ten CDMOs and pick the one with the fastest timeline. The CDMO has to have prior cell therapy manufacturing approvals, a quality system that regulators have audited in that space, and often prior Phase 1 or Phase 2 experience.
This is where the 40% capacity expansion becomes misleading. Much of that new capacity is being built for high-volume mAbs and biosimilars—the formats where demand is predictable and the economics work at scale. Specialized formats remain supply-constrained, and a buyer with an ADC, a CAR-T program, or a biosimilar will find that the CDMO with available slots may not be the one with the deepest expertise in that modality.
Consolidation is reshaping the playing field
Novo Holdings' USD 16.5 billion Catalent deal and Lonza's Vacaville purchase alter global capacity distribution and intensify the fight for large-scale antibody contracts. These mega-deals are concentrating capacity in fewer hands. Novo's acquisition of Catalent creates a platform with massive scale and geographic reach. Lonza's moves signal that even the largest independent players are consolidating to compete. The effect is a bifurcated market: a handful of mega-CDMOs with hundreds of thousands of liters and the ability to absorb large, long-term programs, and a long tail of smaller, specialized shops.
For a buyer, this matters because it changes the negotiating dynamic. A mega-CDMO can demand longer commitments and higher minimum volumes because alternatives are limited. A smaller CDMO may offer flexibility, but it may also lack the redundancy and scale-up pathway that a Phase 3 program needs. The buyer's RFP strategy has to account for this. If the program is a large-volume mAb, the mega-platforms are the only realistic choice, and the conversation is about timeline and cost, not capability. If the program is a niche format, the buyer has more leverage, but the pool of qualified vendors is even smaller.
In April 2026, WuXi Biologics completed the construction of a new 95,000 m² biologics facility equipped with large-scale bioreactors designed for high-volume monoclonal antibody production. This is a signal. WuXi is still building capacity, but the geopolitical wind is at its back in Asia, not in the West. Sponsors in jurisdictions where BIOSECURE does not apply, or who can navigate the regulatory complexity, may still use WuXi. But for US and European sponsors, the calculus has shifted. That capacity is not an option, which means the Western CDMO base has to absorb programs that would have gone to China.
What a buyer should do differently in 2026
First, separate the headline from the reality. When a CDMO says it has 40% capacity growth planned, ask what modality that capacity is for, where it is located, and when it will be GMP-ready. A bioreactor under construction in 2026 will not be qualified until 2027 or 2028. If the program needs manufacturing slots in 2026, that capacity does not exist yet.
Second, assume that your preferred modality is supply-constrained, and plan accordingly. If the program is an ADC, a biosimilar, or a cell therapy, do not expect a quick RFP-to-award cycle. The CDMOs with slots will have other programs in queue. A buyer should start conversations 6–12 months before the program needs manufacturing, not when the manufacturing plan is locked.
Third, stress-test the CDMO's geographic footprint. If the program needs US and European manufacturing for regulatory or supply-chain reasons, confirm that the CDMO has qualified suites in both regions and that they are not overcommitted. A CDMO with a single US facility and a long backlog is not redundant; it is a single point of failure.
Fourth, ask about validation and change control in the context of EMA's revised GMP Annex 15 guidance, which is explicitly considering biological active substance manufacturers and running consultation phases into April 2026, indicating tighter validation and lifecycle change-control expectations for multi-site CDMO networks. If the CDMO operates multiple sites, the question is not just whether each site is compliant, but whether the CDMO has a validated lifecycle change-control process that regulators will accept when the program moves from one site to another or when the CDMO adds a new suite. That is where many mid-sized CDMOs stumble.
Finally, do not assume that valuation or public-market performance predicts execution. Valuation levels across platforms remain differentiated, and equity performance continues to vary across the peer group. A CDMO that is well-capitalized and trading well may still have execution risk if its capacity is overcommitted or its quality systems are not aligned with the latest regulatory expectations. Conversely, a smaller CDMO with lower visibility may have available capacity and deep expertise in your modality. The award decision should be based on fit—modality, timeline, geography, and quality track record—not on the CDMO's market cap.
Sources
- The CDMO Capacity Crunch Persists — Contract Pharma
- The Top Biologics CDMOs in 2026 — BioMed Nexus
- The 2026 Biologics Contract Manufacturing Report — Alira Health
- Biologics CDMO Market Size, Growth & Industry Forecast, 2026-2031 — Mordor Intelligence
- 2026 Biologics CDMO Public Market Update — Alira Health
- Biologics Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Growth Graph by 2034 — Straits Research
- CDMO Market Analysis 2026: Size, Trends & Key Players — Vision Life Sciences
- What to Expect in Pharma Manufacturing in 2026: Industry Leaders Share Their Predictions — PharmaSource